Lp(a) and ASCVD Risk – Hope of the new therapy

June 10, 2022

Xue-Qiao Zhao, MD
Xue-Qiao Zhao, MD
Research Professor of Medicine/Cardiology
Director, Clinical Atherosclerosis Research Lab
University of Washington


Learning Objectives

Upon completion of this program, attendees should be able to

  • Describe the association between higher levels of Lp(a) and increased risk of ASCVD
  • Review the current recommendations of using Lp(a) for risk stratification
  • Introduce the new anti-sense therapy for lowering Lp(a) and the HORIZON trial